Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy
Bjoern Schwander,1 Simona Ravera,2 Giovanni Giuliani,2 Mark Nuijten,3 Stefan Walzer11Assessment-in-Medicine (AiM) GmbH, Loerrach, Germany; 2Roche SpA, Monza, Italy; 3Ars Accessus Medica, Amsterdam (Jisp), NetherlandsBackground: Lung cancer is the leading cause of cancer deaths worldwide (1.38 millio...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-09-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Online Access: | http://www.dovepress.com/cost-comparison-of-second-line-treatment-options-for-late-stage-non-sm-a10894 |